Sanofi SA (SNY)’s New Diabetes Play Moves Forward

Sanofi SA (ADR) (NYSE:SNY) starts the week with a new European Union approval for the type 2 diabetes injectable Lyxumia. The drug belongs to a class of GLP-1 agonists currently dominated by Novo Nordisk A/S (ADR) (NYSE:NVO) and Bristol Myers Squibb Co. (NYSE:BMY). Lyxumia probably won’t jump to the front of that class, but could the new drug bolster Sanofi’s blockbuster insulin as it heads toward patent expiration?

Well-established class
The continually growing market of diabetes treatments inspires a wide range of development tactics. GLP-1 agonists stimulate insulin production without causing hyperglycemia — a common side effect of diabetes treatments. Lyxumia comes to market behind a trio of best-selling drugs that kept growing last year.

Sanofi SA (ADR) (NYSE:SNY)Novo Nordisk leads the field with Victoza, which had 2011 revenues of 6 billion Danish krona (about $952 million at current exchange rates) and a 50% sales growth last year. Amylin developed the once-daily Bydureon and once-weekly Byetta injections, which inspired Bristol-Myers Squibb to buy the company last summer. Bristol recently reported its fiscal year and showed Bydureon’s worldwide net sales  at $78 million and Byetta at $149 million.

Lyxumia would need to beat the existing drugs in either dosage convenience or efficacy if it wanted to knock Victoza from its lead position. But Lyxumia suffered criticism that it’s an efficacy clone of Bydureon. Lyxumia had lackluster results in trials when given on its own. But the drug performed better when paired with insulin.

And that’s the real value of Lyxumia for Sanofi. The company’s $5 billion insulin, Lantus, faces patent expiration in 2015. Placing Lantus into a new combo treatment would help alleviate that financial cliff.

The finances
Lyxumia was licensed from Zealand Pharma, and the contract has Sanofi paying the development and commercialization costs of Lyxumia and any relating combination drugs. Zealand receives milestone payments of $275 million plus global net sales royalties.

Foolish bottom line
Sanofi expects to file for U.S. approval for Lyxumia in the first half of this year. The company’s portfolio is large enough that one new drug won’t become a “make or break” issue. But Lyxumia stands out more than most, thanks to help it can provide Lantus.

The article Sanofi’s New Diabetes Play Moves Forward originally appeared on Fool.com and is written by Brandy Betz.

Fool contributor Brandy Betz has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

10 Top Reasons For Getting Fired

The 3 Best States to Start an LLC

10 Jobs That Allow You to Travel

7 High-Paying Jobs You Can Do From Home

12 Best Cities to Shop in USA

10 Best States To Practice Medicine

The 10 Best States to Have a Business

The 12 Most Expensive Apple (AAPL) Apps in the Market

The 10 Richest Billionaires in the World

10 Biggest Kickstarter Failures

The 10 Best Places to Work At

The Top 10 of Google Inc (GOOGL)’s Most Expensive Acquisitions

13 Best Cities to Visit in South America

10 Most Expensive Works of Art of All Time

The 10 Richest Banks in the World

The 10 Best-Paying Jobs in America (2014)

7 Most Expensive Foods in the World

The World’s Top 10 Earning Authors

Five Wicked and Very Expensive Items (and Other “Stuff”) Sold on eBay

10 Biggest Celebrity Bankruptcies

The Top 10 Highest Paid CEOs in 2014

The 10 Most Expensive Real Estate Cities in America

10 Most Expensive States To Live In America

The 10 Best Airlines in the World

The 10 Best-Selling Cars in 2014

The 10 Best Industries to Invest In

The 10 Most Expensive States to Own a Car In

Top 10 Business Schools in US: 2014 Rankings

Top 20 Female Billionaires in 2014

6 Movies That You Should Watch to Better Understand The Cold War

Top 15 Best Paying Jobs for Women in 2014

Top 6 Things Rich People Do Differently Every Day

5 Retirement Mistakes To Avoid (and Einstein’s Famous Quote)

11 Smartest People in the World

6 Films About the Financial World You Need To Watch (While “The Wolf” is Not Around)

Warren Buffett and Billionaires Are Crazy About These 7 Stocks

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!